Literature DB >> 31119524

Parathyroid Neoplasms: Immunohistochemical Characterization and Long Noncoding RNA (lncRNA) Expression.

Qiqi Yu1, Heather Hardin1, Ying-Hsia Chu1, William Rehrauer1, Ricardo V Lloyd2.   

Abstract

Parathyroid adenomas are slow growing benign neoplasms associated with hypercalcemia, while atypical parathyroid adenomas and parathyroid carcinomas are uncommon tumors and their histologic features may overlap with parathyroid adenomas. LncRNAs participate in transcription and in epigenetic or post-transcriptional regulation of gene expression, and probably contribute to carcinogenesis. We analyzed a group of normal, hyperplastic, and neoplastic parathyroid lesions to determine the best immunohistochemical markers to characterize these lesions and to determine the role of selected lncRNAs in tumor progression. A tissue microarray consisting of 111 cases of normal parathyroid (n = 14), primary hyperplasia (n = 15), secondary hyperplasia (n = 10), tertiary hyperplasia (n = 11), adenomas (n = 50), atypical adenomas (n = 7), and carcinomas (n = 4) was used. Immunohistochemical staining with antibodies against chromogranin A, synaptophysin, parathyroid hormone, and insulinoma-associated protein 1(INSM1) was used. Expression of lncRNAs including metastasis-associated lung adenocarcinoma transcript one (MALAT1), HOX transcript antisense intergenic RNA (HOTAIR), and long intergenic non-protein coding regulator of reprograming (Linc-ROR or ROR) was also analyzed by in situ hybridization and RT-PCR. All of the parathyroid tissues were positive for parathyroid hormone, while most cases were positive for chromogranin A (98%). Synaptophysin was expressed in only 12 cases (11%) and INMS1 was negative in all cases. ROR was significantly downregulated during progression from normal, hyperplastic, and adenomatous parathyroid to parathyroid carcinomas. These results show that parathyroid hormone and chromogranin A are useful markers for parathyroid neoplasms, while synaptophysin and INSM1 are not very sensitive broad-spectrum markers for these neoplasms. LincRNA ROR may function as a tumor suppressor during parathyroid tumor progression.

Entities:  

Keywords:  INMS1; In situ hybridization; Parafibromin; Parathyroid; lncRNA

Mesh:

Substances:

Year:  2019        PMID: 31119524     DOI: 10.1007/s12022-019-9578-3

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  10 in total

1.  Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.

Authors:  Yanping Wang; Heather Hardin; Ying-Hsia Chu; Karla Esbona; Ranran Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 2.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

Review 3.  Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Authors:  Romans Uljanovs; Stanislavs Sinkarevs; Boriss Strumfs; Liga Vidusa; Kristine Merkurjeva; Ilze Strumfa
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 4.  Histone Modification on Parathyroid Tumors: A Review of Epigenetics.

Authors:  Luiz C Conti de Freitas; Rogerio M Castilho; Cristiane H Squarize
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

5.  The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma.

Authors:  Annamaria Morotti; Filomena Cetani; Giulia Passoni; Simona Borsari; Elena Pardi; Vito Guarnieri; Chiara Verdelli; Giulia Stefania Tavanti; Luca Valenti; Cristiana Bianco; Stefano Ferrero; Sabrina Corbetta; Valentina Vaira
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-02       Impact factor: 6.055

Review 6.  Intratumor heterogeneity in human parathyroid tumors.

Authors:  C Verdelli; G S Tavanti; S Corbetta
Journal:  Histol Histopathol       Date:  2020-05-29       Impact factor: 2.303

Review 7.  Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.

Authors:  C Christofer Juhlin; Lori A Erickson
Journal:  Endocr Pathol       Date:  2020-12-02       Impact factor: 3.943

Review 8.  Parathyroid Tumors: Molecular Signatures.

Authors:  Francesca Marini; Francesca Giusti; Teresa Iantomasi; Maria Luisa Brandi
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

9.  Cerebral metastases of parathyroid carcinoma: a case report and literature review.

Authors:  Weiwei Fu; Peng Zhao; Yanan Li; Anjun Zuo; Ling Wei; Fangjie Xin
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

Review 10.  INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View.

Authors:  Zahra Maleki; Akash Nadella; Mohnish Nadella; Gopi Patel; Shivni Patel; Ivana Kholová
Journal:  Diagnostics (Basel)       Date:  2021-11-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.